Pitch Global

Join our team!

How is GTM changing in the AI-World? Yesterday, I spoke at the Pitch Global event at UC Berkeley's SF campus about the changing face of Go-To-Market in the AI world. We're seeing a progression: manual -> AI-assisted -> autonomous AI in sales and marketing. But, there's a real risk of AI overload. Too much AI could actually increase customer acquisition costs, not decrease them. What do you think about this? My thanks to Kaustav Chaudhuri (KC Wisdom), Bhavya Kondapaneni, Nadège Thorez, Henry Tsang, Ph.D., Axel Tillmann, Charles Eason Freddie Seba, Philip Wong, Judith Iglehart, Ed.D, David Xue Jimmy Egas Congratulations to the remarkable startups that delivered outstanding pitches: ?? TelemeTrak – Erik Eklund ?? ViCardia Therapeutics, Inc. – Michael Kokesh ?? Sensorygen – Tom Helfrich Stone ?? Accenga – Gui Orliac ?? Omnny – Igor Tryndin ?? Lucidify – Divya Chander ?? Alterna Card Services – Madeleine Tapia ?? Wayvee Analytics – Anton Timashev

??Investment Announcement ?? Excited to welcome Kosli to our Deutsche Bank VC portfolio family. As part of their $10M financing round, we invested into Kosli alongside Heavybit, Defined Capital, and Transpose Platform! ???? Kosli, an early-stage software development life cycle solution with roots in Norway and the USA, is transforming modern and secure software delivery and change management. The company launched new features today tailored for the financial industry, including support for large user bases, change management automation, and automated audit evidence generation, critical capabilities for regulated environments. ???? Mike Long & James Logan great partnering together and being part of the growth journey of Kosli, Joerg Martin Reeves Thomas Borchers Karen Hui-Ying Wang Denis Roux Joseph Ruscio Cosmin Preda Deutsche Bank Technology, Data & Innovation #VentureCapital #SDLC #corporateventurecapital #imvestment https://lnkd.in/djJesDbq

Microsoft M12, Microsoft's Venture Fund is hiring a Head of Finance

It am pleased to announce Sanofi Ventures’ newest investments in two groundbreaking biotech companies today: Latigo Biotherapeutics, Inc. and Curevo Vaccine. These innovative companies are pushing the boundaries of pain management and infectious disease, and we’re excited to support their journey as they tackle some of the biggest challenges in healthcare. Sanofi Ventures is excited to continue its commitment to chasing the miracles of science by backing visionary teams shaping the future of medicine. Looking forward to partnering with these companies to drive meaningful impact and innovation! Huge thanks to Christopher Gagliardi, Paulina Hill and Monika Vnuk (amongst many others) on the Sanofi side and we look forward to working with the top-tier teams / investors at both companies including: Latigo: Nima Farzan, Neil Singla, MD, Bryan Moyer, Tim Lugo, Kevin Raidy, Tim Anderson, Pedro Alvarez-Urena, Deborah Palestrant, Beth Seidenberg and the Curevo team: George Simon, Greg Curran, David Miller, Giovanni Mariggi, Tal Zaks, Moncef Slaoui, Charlie Petty, Kabeer Aziz, Mario Barro

?? We're excited to announce the 2025 JLABS Investor & Partnering Day on May 7 at the New York Genome Center! ?? This exclusive event is designed to strategically connect life science innovators with similarly aligned investors through tailored opportunities for collaboration and growth. ?? Whether you're seeking funding or potential partnerships or interested in exploring the latest industry trends, this is an event you don't want to miss! ?? What attendees can expect: - Curated one-on-one meetings with top strategically aligned investors - Insights into emerging investment trends shaping life sciences in 2025 - An expert panel discussion featuring key insights from J&J thought leaders - Networking opportunities with industry leaders during our evening reception ?? Don't miss this opportunity to expand your network, gain valuable insights, and unlock new growth opportunities in life sciences. ? ?? With a highly competitive application process with limited spots, innovators aligned with the?the J&J business areas of interest?and affiliated platform technologies are encouraged to apply. This will increase the likelihood of acceptance.? ?? Apply today for a chance to be selected - Application deadline is April 4:?https://lnkd.in/eSeja_Sv ? #MyCompany #LifeSciencesInnovation #StartupFunding #JLABS #InvestorConnections

We’re hiring! We’re adding an investor to our health team at Andreessen Horowitz. It’s an incredibly fun and fulfilling job. We get to invest in and support amazing founders building companies that are improving human health and reimagining what healthcare can look like. Please reach out if interested!

At General Catalyst, we're committed to leveraging technology to advance human health. That's why Rachit N., Alessandra Cesano and I couldn’t be more excited to partner with Arndt Schottelius, MD PhD, John McCafferty, Aneesh Karatt Vellatt, Eva-Lotta Allan and the entire Maxion Therapeutics team by leading their $72M Series A financing. Maxion's proprietary Knotbody platform significantly advances the potential for treating diseases in which targeting ion channels and GPCRs with biologics has previously been impossible.?Link in the comments if you'd like to read more about what Maxion is working on and why we invested. Proud to partner with Sohaib Mir at LifeArc Ventures, Tim Funnell at Monograph Capital, Lucy Edwardes Jones at BGF, Emma Johnson at British Patient Capital, Derek Yoon at Solasta Ventures, and Laura A. Lane at Eli Lilly and Company. #VentureBeyond, General Catalyst, Hemant Taneja, Chris Bischoff, Holly Maloney, Caitlin Donovan, Reva Nohria, Kenneth C. Frazier, Robin Washington, Candace Richardson, Alexandre Momeni, Tyler Olkowski, Rey P., Dylan S., Anant Pai, Daryl Tol

Exciting Opportunity Senior Director Business Development (Investments) Join us as the Senior Director of Business Development (Investments) in Princeton, reporting directly to the Executive Director of Business Development. This pivotal role will play a crucial part in driving global business development innovation initiatives. Key Requirements: - Extensive experience in the pharmaceutical industry or biotech venture capital/venture creation. - Strong scientific and development background. - Proven track record in project and people leadership. - Business and strategic acumen. - Excellent communication skills. Qualifications: - Advanced degree (MS, MBA, PharmD, JD, MD, or PhD). If you are ready to take on this challenging yet rewarding role, apply now to be part of a dynamic team driving innovation in the industry. #BusinessDevelopment #PrincetonOpportunity #Otsuka Carla Lema Tome, MBA, PhD John Kraus Tim Brady